癌症会耗尽机体内的T细胞，这是因为敌对的肿瘤微环境会消耗T细胞中的线粒体活性，导致T细胞耗竭，进而阻碍了过继细胞疗法（Adoptive Cell Transfer ...

EVA Pharma is one of the fastest-growing healthcare companies in the Middle East and Africa, with an extensive pan-African presence, while operating in more than 70 countries worldwide. For more ...

Nevertheless, Anixa hopes to develop the first approved CAR T-cell therapy for a solid tumor indication. The company has identified a protein called the follicle-stimulating hormone receptor (FSHR ...

Liu concluded, “As our XOFLX system only uses one transfer plasmid or no plasmid at all for LVV production, ... a CD20/CD19-targeting CAR T-cell therapy to treat B-cell malignancies, ...

AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s ...

AGC Biologics will commence cell therapy process development and clinical manufacturing services at AGC Inc.’s Yokohama ...

On February 13, Allogene Therapeutics published new long-term follow-up data on cemacabtagene ansegedleucel, showing the investigative allogeneic chimeric antigen receptor (CAR) T-cell therapy ...

CAR-T cell therapy, which involves genetically engineered T-lymphocytes targeting cancer cells, has shown high efficacy in blood cancers and is being explored for solid tumors and autoimmune diseases.

Cellular Origins has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform ...

Researchers found that, upon CAR T-cell therapy, microglia – the brain’s immune cells – produces chemicals like cytokines and chemokines as part of its inflammatory response.

CAR-T cell therapy for hematologic cancers is now available at St. George Regional Hospital. Jacqueline, a Las Vegas patient who traveled to Salt Lake City for the treatment, said it saved her life.

Local immune effector cell–associated toxicity syndrome is a newly identified side effect observed in many patients receiving CD19-targeting CAR T-cell therapy for autoimmune conditions.